Dark Forest Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Dark Forest Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,248	Closed	-$1.45M	–	1019
2025 Q4	$1.45M	Buy	+10,248	New	+$1.48M	0.07%	519
2025 Q2	–	Sell	-3,433	Closed	-$380K	–	1406
2025 Q1	$380K	Buy	3,433 +1,808	+111%	+$229K	0.02%	1007
2024 Q4	$222K	Buy	+1,625	New	+$201K	0.03%	785
2023 Q4	–	Sell	-8,864	Closed	-$997K	–	884
2023 Q3	$997K	Buy	+8,864	New	+$933K	0.08%	410
2023 Q2	–	Sell	-1,591	Closed	-$161K	–	1267
2023 Q1	$161K	Buy	+1,591	New	+$166K	0.04%	486
2021 Q4	–	Sell	-106	Closed	-$10K	–	1665
2021 Q3	$10K	Buy	+106	New	+$10K	﹤0.01%	988

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dark Forest Capital Management's NBIX Position: Q1 2026 in Review

Dark Forest Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 10,248 shares — an estimated $1.45M sold.

Dark Forest Capital Management first reported a position in NBIX in Q3 2021 and held it in 6 quarters. The position peaked at $1.45M in Q4 2025. 697 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Dark Forest Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
Dark Forest Capital Management sold 10,248 Neurocrine Biosciences shares in Q1 2026, an estimated $1.45M.
Dark Forest Capital Management first reported a position in Neurocrine Biosciences in Q3 2021 and held it in 6 quarters.
Dark Forest Capital Management's Neurocrine Biosciences position peaked at $1.45M in Q4 2025.
697 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Dark Forest Capital Management's 13F filing for Q1 2026, filed 15 May 2026.